Replies to post #414992 on NorthWest Biotherapeutics Inc (NWBO)

[SecureInvest]

At the end of the last fiscal year, CRL had not yet acquired Cognate, which is why there's no mention of CRL in the 10K.

The wording in the 'risk factors' section is never anything to worry about. I am not worried about them saying they may have to enter into new manufacturing agreements. Flaskworks is likely not included in any of the agreements with Cognate, as they were acquired last year. That in itself would require a new agreement.

Even with an existing agreement in place, they could have been negotiating a new agreement with CRL at the time of the release of the 10K, which would include Flaskworks.

[VikingInvest]

You could be right. I do believe we had an agreement with Cognate during the trial phase that would give them manufacturing rights for a pre determined amount of years after approval (probably just for the US)

Them saying they would need to enter into new agreements might be for territories outside the US. As for Sawston, I think they did the initial space for the compassionate program and to make sure it was done as fast as possible. I don't think they will have a lot of trouble expanding the production facility once they get the ball rolling with the approval process or even after approval.